What is Jeuveau?
Jeuveau (prabotulinumtoxinA-xvfs) is a neuromodulator made by Evolus and approved by the FDA in 2019 for the temporary improvement of moderate to severe glabellar lines, the vertical "11" lines between the eyebrows. It is the first neurotoxin in the US developed purely for aesthetic use, which is why it is sometimes nicknamed "Newtox." It uses a 900 kDa botulinum toxin type A complex structurally similar to Botox, so injection technique, dosing and results are comparable.
Jeuveau works by blocking the nerve signals that make the corrugator and procerus muscles contract. With those muscles relaxed, the skin above them stops creasing and existing lines soften. In clinical trials, about half of patients showed improvement by day two and roughly 68 to 70 percent reached a two-grade improvement by day 30. Results typically last three to four months, and most patients are treated about three times a year. Providers also use Jeuveau off-label on forehead lines, crow's feet and other expression lines in the same way they use Botox or Dysport.